325 related articles for article (PubMed ID: 28272463)
1. PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis.
Wu J; Hong D; Zhang X; Lu X; Miao J
Sci Rep; 2017 Mar; 7():44173. PubMed ID: 28272463
[TBL] [Abstract][Full Text] [Related]
2. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V
Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515
[TBL] [Abstract][Full Text] [Related]
3. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis.
Nishino M; Giobbie-Hurder A; Hatabu H; Ramaiya NH; Hodi FS
JAMA Oncol; 2016 Dec; 2(12):1607-1616. PubMed ID: 27540850
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Luo W; Wang Z; Tian P; Li W
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1851-1859. PubMed ID: 30019319
[TBL] [Abstract][Full Text] [Related]
5. Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution.
Sukari A; Nagasaka M; Alhasan R; Patel D; Wozniak A; Ramchandren R; Vaishampayan U; Weise A; Flaherty L; Jang H; Kim S; Gadgeel S
Anticancer Res; 2019 Feb; 39(2):781-790. PubMed ID: 30711957
[TBL] [Abstract][Full Text] [Related]
6. Risk of Pneumonitis with the Use of Different Immune Checkpoint Inhibitors in a Mexican Population.
Dávila-Dupont D; Motola-Kuba D; Dorantes-Heredia R; González-Alonso BK; Alcántara-Velarde T; García-Santisteban R; Martínez-Sámano JE; Grimaldo-Roque HJ; Ruiz-Morales JM
Oncology; 2019; 96(5):268-272. PubMed ID: 30861515
[TBL] [Abstract][Full Text] [Related]
7. The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials.
Buti S; Bersanelli M
Future Oncol; 2016 Sep; 12(18):2061-3. PubMed ID: 27168416
[No Abstract] [Full Text] [Related]
8. Programmed cell death 1 (PD-1)/PD-ligand 1(PD-L1) inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer.
Sun Y; Shao C; Li S; Xu Y; Xu K; Zhang Y; Huang H; Wang M; Xu Z
Asia Pac J Clin Oncol; 2020 Dec; 16(6):299-304. PubMed ID: 32757454
[TBL] [Abstract][Full Text] [Related]
9. Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer.
Nishino M; Chambers ES; Chong CR; Ramaiya NH; Gray SW; Marcoux JP; Hatabu H; Jänne PA; Hodi FS; Awad MM
Cancer Immunol Res; 2016 Apr; 4(4):289-93. PubMed ID: 26865455
[TBL] [Abstract][Full Text] [Related]
10. Risk of Pneumonitis Associated with Programmed Cell Death 1 Inhibitors in Cancer Patients: A Meta-analysis.
Zhang S; Liang F; Zhu J; Chen Q
Mol Cancer Ther; 2017 Aug; 16(8):1588-1595. PubMed ID: 28446641
[TBL] [Abstract][Full Text] [Related]
11. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
12. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
Cho JY; Kim J; Lee JS; Kim YJ; Kim SH; Lee YJ; Cho YJ; Yoon HI; Lee JH; Lee CT; Park JS
Lung Cancer; 2018 Nov; 125():150-156. PubMed ID: 30429014
[TBL] [Abstract][Full Text] [Related]
13. Pneumonitis From Anti-PD-1/ PD-L1 Therapy.
Balaji A; Verde F; Suresh K; Naidoo J
Oncology (Williston Park); 2017 Oct; 31(10):739-46, 754. PubMed ID: 29083466
[TBL] [Abstract][Full Text] [Related]
14. Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors.
Kaymakcalan MD; Je Y; Sonpavde G; Galsky M; Nguyen PL; Heng DY; Richards CJ; Choueiri TK
Br J Cancer; 2013 Jun; 108(12):2478-84. PubMed ID: 23736025
[TBL] [Abstract][Full Text] [Related]
15. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus.
Maroto JP; Hudes G; Dutcher JP; Logan TF; White CS; Krygowski M; Cincotta M; Shapiro M; Duran I; Berkenblit A
J Clin Oncol; 2011 May; 29(13):1750-6. PubMed ID: 21444868
[TBL] [Abstract][Full Text] [Related]
16. Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials.
Iacovelli R; Palazzo A; Mezi S; Morano F; Naso G; Cortesi E
Acta Oncol; 2012 Sep; 51(7):873-9. PubMed ID: 22909392
[TBL] [Abstract][Full Text] [Related]
17. PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course.
Nishino M; Ramaiya NH; Awad MM; Sholl LM; Maattala JA; Taibi M; Hatabu H; Ott PA; Armand PF; Hodi FS
Clin Cancer Res; 2016 Dec; 22(24):6051-6060. PubMed ID: 27535979
[TBL] [Abstract][Full Text] [Related]
18. Treatment with a programmed cell death-1-specific antibody has little effect on afatinib- and naphthalene-induced acute pneumonitis in mice.
Hamada N; Yanagihara T; Suzuki K; Ogata-Suetsugu S; Harada E; Mikumo H; Arimura-Omori M; Nakanishi Y
Biochem Biophys Res Commun; 2017 Sep; 491(3):656-661. PubMed ID: 28756224
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Therapy in Renal Cell Carcinoma.
Lee CH; Motzer RJ
Cancer J; 2016; 22(2):92-5. PubMed ID: 27111903
[TBL] [Abstract][Full Text] [Related]
20. Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma.
de Velasco G; Krajewski KM; Albiges L; Awad MM; Bellmunt J; Hodi FS; Choueiri TK
Cancer Immunol Res; 2016 Jan; 4(1):12-7. PubMed ID: 26589768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
